Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Holdings Boosted by Financial Sense Advisors Inc.

Financial Sense Advisors Inc. lifted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 63.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 405,421 shares of the company's stock after buying an additional 157,421 shares during the period. Teva Pharmaceutical Industries makes up 1.7% of Financial Sense Advisors Inc.'s portfolio, making the stock its 13th biggest position. Financial Sense Advisors Inc.'s holdings in Teva Pharmaceutical Industries were worth $6,231,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of TEVA. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 197,885.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after acquiring an additional 22,044,407 shares in the last quarter. FMR LLC lifted its stake in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares in the last quarter. Duquesne Family Office LLC raised its stake in Teva Pharmaceutical Industries by 530.1% during the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock valued at $198,303,000 after buying an additional 7,569,450 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Teva Pharmaceutical Industries by 472.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock valued at $96,078,000 after buying an additional 5,186,592 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Teva Pharmaceutical Industries by 416.0% during the first quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock valued at $91,973,000 after buying an additional 4,824,247 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president directly owned 9,989 shares of the company's stock, valued at $170,012.78. This represents a 38.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.49% of the stock is owned by company insiders.

Analyst Ratings Changes

TEVA has been the topic of several research reports. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen cut Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Finally, Truist Financial began coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded down $0.20 on Thursday, reaching $16.39. The company's stock had a trading volume of 6,948,691 shares, compared to its average volume of 12,028,592. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a market capitalization of $18.79 billion, a P/E ratio of -14.24, a price-to-earnings-growth ratio of 0.96 and a beta of 0.60. The firm has a fifty day moving average of $16.95 and a two-hundred day moving average of $16.87. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same period in the prior year, the company posted $0.48 EPS. The business's revenue for the quarter was up 1.9% compared to the same quarter last year. As a group, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.